The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Open accessAbstract
IMPORTANCE: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE: To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).16”
From Type 1 diabetes (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most individuals without diabetes who have only one autoantibody will not develop type 1 diabetes, as the 10-year risk is about 15% (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a nearcertain predictor of clinical diabetes (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a near-certain predictor of clinical diabetes (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A seminal analysis of four different birth cohorts from the USA, Finland and Germany demonstrated that the presence of a single islet autoantibody is associated with a 13% risk of developing type 1 diabetes over 15 years. In contrast, having two or more antibodies is associated with a 70% risk over 10 years of observation and an 84% risk over 15 years63.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, studies of the offspring of people with diabetes show that young children with multiple autoantibodies develop diabetes during childhood [ 12 ]”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“In children with only one persistent islet autoantibody, the risk of diabetes within 10 years is 15% while two or more islet autoantibodies predict type 1 diabetes in 70% within 10 years (408,409).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Self-citationGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Self-citationQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes
Bonifacio, E. E., Shattock, M., Dean, B. M., Bottazzo, G. F., Bingley, P. J., Gale, E., & Dunger, D. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)90013-u · Cited by 344
Self-citationStratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E. E., & Ziegler, A. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 276
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationPREDICTING INSULIN-DEPENDENT DIABETES
Tarn, A., Dean, B., Schwarz, G., Thomas, J. M., Ingram, D., Bottazzo, G. F., & Gale, E. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91601-7 · Cited by 260
Cited by
Sorted by citations
Items 301–400 of 1,001
Steck, A. K., Fouts, A., Miao, D., Zhao, Z., Dong, F., Sosenko, J. M., Gottlieb, P. A., Rewers, M., Yu, L., & and the TrialNet Study Group (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0316 · Cited by 37
Self-citationDriscoll, K. A., Tamura, R., Johnson, S. B., Gesualdo, P., Clasen, J. L., SMITH, L. B., Jacobsen, L. M., Larsson, H. E., Haller, M. J., & the TEDDY Study Group (2020) · Pediatric Diabetes · doi:10.1111/pedi.13149 · Cited by 37
Screening and Prevention of Type 1 Diabetes: Where Are We?
Simmons, K. M., & Sims, E. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad328 · Cited by 41
A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis
Wuest, S. C., Mexhitaj, I., Chai, N. R., Romm, E., Scheffel, J., Xu, B., Lane, K. C., Wu, T., & Bielekova, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105434 · Cited by 37
Kodama, K., Zhao, Z., Toda, K., Yip, L., Fuhlbrigge, R., Miao, D., Fathman, C. G., Yamada, S., Butte, A. J., & Yu, L. (2016) · Diabetes · doi:10.2337/db15-1308 · Cited by 36
Kent, S. C., Mannering, S. I., Michels, A. W., & Babon, J. A. B. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0915-y · Cited by 36
Definition, Diagnosis and Classification of Diabetes Mellitus
Puchulu, F. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_2 · Cited by 39
SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood
Lugar, M., Eugster, A., Achenbach, P., Berge, T. V. D., Berner, R., Besser, R. E. J., Casteels, K., Larsson, H. E., Gemulla, G., Kordonouri, O., et al. (2023) · JAMA · doi:10.1001/jama.2023.16348 · Cited by 38
Self-citationNathan, B. M., REDONDO, M. J., Ismail, H. M., Jacobsen, L. M., Sims, E. K., Palmer, J. P., Skyler, J. S., Bocchino, L. E., Geyer, S. M., & Sosenko, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0944 · Cited by 36
Gonçalves, L. M., Qadir, M. M. F., Boulina, M. E., Makhmutova, M., Pereira, E., & Almaça, J. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112913 · Cited by 35
Liu, Y., Rafkin, L. E., Matheson, D., Henderson, C., Boulware, D. C., Besser, R. E. J., Ferrara, C., Yu, L., Steck, A. K., Bingley, P. J., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13338 · Cited by 36
Self-citationType 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Cabrera, S. M., Engle, S., Kaldunski, M. L., Jia, S., Geoffrey, R., Simpson, P. M., Szabó, A., Speake, C., Greenbaum, C. J., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4708-x · Cited by 35
Diagnosis, Therapy and Follow-up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0869-0210 · Cited by 36
Gauci, M.-L., Boudou, P., Baroudjian, B., Vidal-Trécan, T., Meda, L. D., Madelaine, I., Basset‐Séguin, N., Bagot, M., Pagès, C., Mourah, S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2178-0 · Cited by 36
Bediaga, N. G., Suen, C. S. N. L. W., Haller, M. J., Gitelman, S. E., Evans‐Molina, C., Gottlieb, P. A., Hippich, M., Ziegler, A., Lernmark, Å., DiMeglio, L. A., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05523-2 · Cited by 35
Self-citationThompson, P. J., Pipella, J., Rutter, G. A., Gaisano, H. Y., & Santamaría, P. (2023) · Diabetologia · doi:10.1007/s00125-023-05970-z · Cited by 38
Hoffmann, L. E., Kohls, M., Arnolds, S., Achenbach, P., Bergholdt, R., Bonifacio, E. E., Bosi, E., Gündert, M., Hoefelschweiger, B. K., Hummel, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088522 · Cited by 46
Self-citationWoittiez, N. J. C., & Roep, B. O. (2015) · Immunotherapy · doi:10.2217/imt.14.104 · Cited by 35
Peptide serum markers in islet autoantibody-positive children
von Toerne, C., Laimighofer, M., Achenbach, P., Beyerlein, A., Gala, T. D. L. H., Krumsiek, J., Theis, F. J., Ziegler, A. G., & Hauck, S. M. (2016) · Diabetologia · doi:10.1007/s00125-016-4150-x · Cited by 35
Self-citationProteomic Landscape of Patient-Derived CD4+ T Cells in Recent-Onset Type 1 Diabetes
Lepper, M. F., Ohmayer, U., von Toerne, C., Maison, N., Ziegler, A., & Hauck, S. M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00712 · Cited by 36
Self-citationAntibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders
Pollak, T. A., Rogers, J. P., Nagele, R. G., Peakman, M., Stone, J. M., David, A. S., & McGuire, P. K. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby021 · Cited by 37
What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?
Williams, C. L., & Long, A. E. (2019) · Diabetologia · doi:10.1007/s00125-019-04975-x · Cited by 35
A Systematic Review of Childhood Diabetes Research in the Middle East Region
Saraswathi, S., Al‐Khawaga, S., Elkum, N. B., & Hussain, K. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00805 · Cited by 35
Emerging Roles of Gut Virome in Pediatric Diseases
Fulci, V., Stronati, L., Cucchiara, S., Laudadio, I., & Carissimi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084127 · Cited by 36
The pathophysiology, presentation and classification of Type 1 diabetes
Aamodt, K. I., & Powers, A. C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16628 · Cited by 52
Role of humoral beta-cell autoimmunity in type 1 diabetes
Knip, M., Siljander, H., Ilonen, J., Simell, O., & Veijola, R. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12386 · Cited by 34
Self-citationYue, Y., Tang, Y., Tang, J., Shi, J., Zhu, T., Huang, J., Qiu, X., Zeng, Y., Li, W.-G., Qu, Y., et al. (2018) · Epidemiology and Infection · doi:10.1017/s0950268818002455 · Cited by 32
Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes
Claessens, L. A., Wesselius, J., van Lummel, M., Laban, S., Mulder, F. F. M., Mul, D., Nikolic, T., Aanstoot, H., Koeleman, B. P. C., & Roep, B. O. (2019) · Diabetologia · doi:10.1007/s00125-019-05032-3 · Cited by 34
The changing face of paediatric diabetes
SHAH, A. S., & Nadeau, K. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05075-6 · Cited by 36
Risk Factors for Type 1 Diabetes
Rewers, M., Stene, L. C., & Norris, J. M. (2018) · Europe PMC (PubMed Central) · Cited by 34
Self-citationCefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes Care · doi:10.2337/dci21-0051 · Cited by 36
Acevedo-Calado, M., James, E. A., Morran, M. P., Pietropaolo, S. L., Ouyang, Q., Arribas-Layton, D., Songini, M., Liguori, M., Casu, A., Auchus, R. J., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1527 · Cited by 35
Diabetes associated with immune checkpoint inhibition: presentation and management challenges
Galligan, A., Xu, W., Fourlanos, S., Nankervis, A. J., Chiang, C. Y., Mant, A. M., Parente, P., Rischin, D., Krishnamurthy, B., Sandhu, S. K., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13762 · Cited by 33
Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
Kroger, C. J., Clark, M., Qi, K., & Tisch, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01891 · Cited by 35
Alagpulinsa, D. A., Cao, J. J. L., Sobell, D., & Poznansky, M. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.011 · Cited by 33
Tang, X., Kusmartseva, I., Kulkarni, S., Posgai, A. L., Speier, S., Schatz, D. A., Haller, M. J., Campbell‐Thompson, M., Wasserfall, C. H., Roep, B. O., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.11.010 · Cited by 33
Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
Torun, A., Hupalowska, A., Trzonkowski, P., Kierkuś, J., & Pyrzyńska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642166 · Cited by 40
Lind, A., Cortez, F. D. J., Ramelius, A., Bennet, R., Robinson, P. V., Seftel, D., Gebhart, D., Tandel, D., Maziarz, M., Agardh, D., et al. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113265 · Cited by 36
Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Fousteri, G., Ippolito, E., Ahmed, R., & Hamad, A. R. A. (2017) · Current Diabetes Reviews · doi:10.2174/1573399812666160427104157 · Cited by 35
Bonifacio, E. E., & Ziegler, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16354 · Cited by 35
Self-citationBonifacio, E. E., Krumsiek, J., Winkler, C., Theis, F. J., & Ziegler, A. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0526-2 · Cited by 32
Self-citationBonifacio, E. E., Mathieu, C., Nepom, G. T., Ziegler, A., Anhalt, H., Haller, M. J., Harrison, L. C., Hebrok, M., Kushner, J. A., Norris, J. M., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4144-8 · Cited by 32
Self-citationHanna, S. J., Powell, W. E., Long, A. E., Robinson, E., Davies, J. E., Megson, C., Howell, A., Jones, T. J., Ladell, K., Price, D. A., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05114-7 · Cited by 32
Basta, G., Montanucci, P., & Calafiore, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13372 · Cited by 34
Extracellular Vesicles in Type 1 Diabetes: A Versatile Tool
Suire, C. N., & Hade, M. D. (2022) · Bioengineering · doi:10.3390/bioengineering9030105 · Cited by 33
Vehik, K., Boulware, D. C., Killian, M., Rewers, M., McIndoe, R., Toppari, J., Lernmark, Å., Akolkar, B., Ziegler, A., Rodriguez, H., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0828 · Cited by 32
Self-citationGAD autoantibody affinity in schoolchildren from the general population
Bender, C., Schlosser, M., Christen, U., Ziegler, A. G., & Achenbach, P. (2014) · Diabetologia · doi:10.1007/s00125-014-3294-9 · Cited by 32
Self-citationWentworth, J. M., Oakey, H., Craig, M. E., Couper, J., Cameron, F. J., Davis, E. A., Lafferty, A. R. A., Harris, M. A., Wheeler, B. J., Jefferies, C., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13422 · Cited by 31
Autoimmune diseases: targets, biology, and drug discovery
Li, S.-J., Wu, Y., Chen, J.-H., Shen, S.-Y., Duan, J., & Xu, H. E. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01207-2 · Cited by 34
The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)
Groups, T. D. T. 1. T. A. D. P. T.-T. 1. S., Sosenko, J. M., Skyler, J. S., & Palmer, J. P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0626-1 · Cited by 31
Predicting progression to diabetes in islet autoantibody positive children
Steck, A. K., Dong, F., Frohnert, B. I., Waugh, K., Hoffman, M., Norris, J. M., & Rewers, M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.01.006 · Cited by 32
Self-citationThe countdown to type 1 diabetes: when, how and why does the clock start?
Ziegler, A.-G. (2023) · Diabetologia · doi:10.1007/s00125-023-05927-2 · Cited by 30
Self-citationLeichter, S. B., Felton, J. L., Rasmussen, C. G., Rizzuto, P., Bellini, N. J., Ebekozien, O. A., & Schulman‐Rosenbaum, R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf194 · Cited by 32
Type 1 diabetes presenting in adults: Trends, diagnostic challenges and unique features
Evans‐Molina, C., & Oram, R. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16402 · Cited by 34
TEDDY study group, Köhler, M., Beyerlein, A., Vehik, K., Greven, S., Umlauf, N., Lernmark, Å., Hagopian, W., Rewers, M., She, J., et al. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1033-7 · Cited by 31
Self-citationRapini, N., Schiaffini, R., & Fierabracci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062103 · Cited by 31
Mucosal-associated invariant T cell alterations during the development of human type 1 diabetes
Gazali, A. M., Schroderus, A., Näntö‐Salonen, K., Rintamäki, R. M., Pihlajamäki, J., Knip, M., Veijola, R., Toppari, J., Ilonen, J., & Kinnunen, T. T. (2020) · Diabetologia · doi:10.1007/s00125-020-05257-7 · Cited by 29
Self-citationLi, Q., Liu, X., Yang, J., Erlund, I., Lernmark, Å., Hagopian, W., Rewers, M., She, J., Toppari, J., Ziegler, A., et al. (2020) · Diabetes · doi:10.2337/db20-0696 · Cited by 30
Self-citationPenaforte-Saboia, J. G., Couri, C. E. B., Albuquerque, N. V., Silva, V. L. L., Olegário, N. B. D. C., Fernandes, V. O., & Montenegro, R. M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s294742 · Cited by 30
Vecchione, A. M., Jofra, T., Gerosa, J., Shankwitz, K., Fonte, R. D., Galvani, G., Ippolito, E., Cicalese, M. P., Schultz, A., Seay, H. R., et al. (2021) · Diabetes · doi:10.2337/db21-0091 · Cited by 32
T peripheral helper cells in autoimmune diseases: What do we know?
Huang, Y., Ba, X., Han, L., Wang, H., Lin, W., Chen, Z., & Tu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145573 · Cited by 32
Lynch, K., Lee, H., Törn, C., Vehik, K., Krischer, J. P., Larsson, H. E., Haller, M. J., Hagopian, W., Rewers, M., She, J., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.09.005 · Cited by 33
Self-citationMehdi, A. M., Hamilton‐Williams, E. E., Cristino, A. S., Ziegler, A. G., Bonifacio, E. E., Cao, K. L., Harris, M. A., & Thomas, R. (2018) · JCI Insight · doi:10.1172/jci.insight.98212 · Cited by 30
Self-citationUnderstanding Islet Autoantibodies in Prediction of Type 1 Diabetes
Jia, X., & Yu, L. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad160 · Cited by 33
Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023
Pleus, S., Tytko, A., Landgraf, R., Heinemann, L., Werner, C., Müller‐Wieland, D., Ziegler, A., Müller, U., Freckmann, G., Kleinwechter, H. J., et al. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6643 · Cited by 37
Self-citationTargeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications
Naseri, R., Navabi, S. J., Samimi, Z., Mishra, A. P., Nigam, M., Chandra, H., Olatunde, A., Tijjani, H., Morais‐Urano, R. P., & Farzaei, M. H. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00327-y · Cited by 31
miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes
Scherm, M. G., & Daniel, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.606322 · Cited by 30
Immunological Issues After Stem Cell-Based β Cell Replacement
Sordi, V., Pellegrini, S., & Piemonti, L. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0901-4 · Cited by 30
Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside
Brawerman, G. M., & Thompson, P. J. (2020) · Biomolecules · doi:10.3390/biom10121681 · Cited by 29
Karpov, D. S., Sosnovtseva, A. O., Pylina, S. V., Bastrich, A., Petrova, D. A., Kovalev, M. A., Shuvalova, A. I., Константиновна, Е. А., & Mokrysheva, N. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417320 · Cited by 30
Bell, K. J., Brodie, S., Couper, J., Colman, P. G., Davis, E. A., Deed, G., Hagopian, W., Haynes, A., Hendrieckx, C., Henry, A., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15419 · Cited by 30
Screening children for type 1 diabetes‐associated antibodies at community health fairs
Simmons, K. M., Youngkin, E. M., Alkanani, A. K., Miao, D., McDaniel, K. A., Yu, L., & Michels, A. W. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12902 · Cited by 28
The crucial role of early-life gut microbiota in the development of type 1 diabetes
Zhou, H., Sun, L., Zhang, S., Zhao, X. Y., Gang, X., & Wang, G. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01563-z · Cited by 30
Lipid mediators and biomarkers associated with type 1 diabetes development
Nelson, A. J., Stephenson, D., Bone, R. N., Cardona, C. L., Park, M. A., Tusing, Y. G., Lei, X., Kokotos, G., Graves, C. L., Mathews, C. E., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138034 · Cited by 28
Haris, B., Ahmed, I., Syed, N., Almabrazi, H., Saraswathi, S., Al‐Khawaga, S., Saeed, A. Z., Mundekkadan, S., Mohammed, I., Sharari, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98460-4 · Cited by 28
Altered islet prohormone processing: a cause or consequence of diabetes?
Ramzy, A., & Kieffer, T. J. (2021) · Physiological Reviews · doi:10.1152/physrev.00008.2021 · Cited by 27
Lessons and gaps in the prediction and prevention of type 1 diabetes
Mameli, C., Triolo, T. M., Chiarelli, F., Rewers, M., Zuccotti, G., & Simmons, K. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106792 · Cited by 33
Self-citationA Swedish approach to the prevention of type 1 diabetes
Larsson, H. E. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12325 · Cited by 28
Fouts, A., Pyle, L. L., Yu, L., Miao, D., Michels, A. W., Krischer, J. P., Sosenko, J. M., Gottlieb, P. A., Steck, A. K., & the Type 1 Diabetes TrialNet Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0302 · Cited by 30
Self-citationEarly life origin of type 1 diabetes
Knip, M., Luopajärvi, K., & Härkönen, T. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0665-6 · Cited by 29
Self-citationIhantola, E., Viisanen, T., Gazali, A. M., Näntö‐Salonen, K., Juutilainen, A., Moilanen, L., Rintamäki, R. M., Pihlajamäki, J., Veijola, R., Toppari, J., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701199 · Cited by 28
Self-citationType 1 diabetes mellitus prevention: present and future
Henriques, F. L., Buckle, I., & Forbes, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01128-6 · Cited by 32
Hybrid insulin peptides are neo-epitopes for CD4 T cells in autoimmune diabetes
Baker, R. L., Jamison, B. L., & HASKINS, K. M. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000490 · Cited by 27
Temporal development of T cell receptor repertoires during childhood in health and disease
Mitchell, A. M., Baschal, E. E., McDaniel, K. A., Simmons, K. M., Pyle, L. L., Waugh, K., Steck, A. K., Yu, L., Gottlieb, P. A., Rewers, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161885 · Cited by 26
Self-citationStrollo, R., Vinci, C., Man, Y. K. S., Bruzzaniti, S., Piemonte, E., Alhamar, G., Briganti, S., Malandrucco, I., Tramontana, F., Fanali, C., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05812-4 · Cited by 27
Fyvie, M. J., & Gillespie, K. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1158278 · Cited by 29
Belgian Diabetes Registry, Dalem, A. V., Demeester, S., Balti, E. V., Decochez, K., Weets, I., Vandemeulebroucke, E., de Velde, U. V., Walgraeve, A., Seret, N., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3761-y · Cited by 26
Flexible Bayesian additive joint models with an application to type 1 diabetes research
Köhler, M., Umlauf, N., Beyerlein, A., Winkler, C., Ziegler, A., & Greven, S. (2017) · Biometrical Journal · doi:10.1002/bimj.201600224 · Cited by 30
Self-citationSosenko, J. M., Yu, L., Skyler, J. S., Krischer, J. P., Gottlieb, P. A., Boulware, D. C., Miao, D., Palmer, J. P., & Steck, A. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0243 · Cited by 27
Self-citationNeoepitopes: a new take on beta cell autoimmunity in type 1 diabetes
Mannering, S. I., Carluccio, A. R. D., & Elso, C. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4760-6 · Cited by 27
Sims, E. K., Cuthbertson, D. D., Ferrat, L. A., Bosi, E., Evans‐Molina, C., DiMeglio, L. A., Nathan, B. M., Ismail, H. M., Jacobsen, L. M., REDONDO, M. J., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06382-x · Cited by 27
Health economic considerations of screening for early type 1 diabetes
Rewers, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16522 · Cited by 27
Self-citationT1D Autoantibodies: room for improvement?
Yu, L., Zhao, Z., & Steck, A. K. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000348 · Cited by 27
Self-citationBorg, D. J., Yap, F. Y. T., Keshvari, S., Simmons, D. G., Gallo, L. A., Fotheringham, A. K., Zhuang, A., Slattery, R. M., Hasnain, S. Z., Coughlan, M. T., et al. (2017) · Islets · doi:10.1080/19382014.2017.1405189 · Cited by 26
Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes
Aslamy, A., Oh, E., Ahn, M., Moin, A. S. M., Chang, M., Duncan, M., Hacker-Stratton, J., El-Shahawy, M. A., KANDEEL, F. R., DiMeglio, L. A., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02492 · Cited by 26
B cell helper T cells and type 1 diabetes
Vandamme, C., & Kinnunen, T. T. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12943 · Cited by 27
Kahkoska, A. R., & Dabelea, D. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.007 · Cited by 30
Felton, J. L., Griffin, K., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Evans‐Molina, C., DiMeglio, L. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00357-y · Cited by 27
Self-citationMikk, M., Heikkinen, T., El‐Amir, M. I., Kiviniemi, M., Laine, A., Härkönen, T., Veijola, R., Toppari, J., Knip, M., Ilonen, J., et al. (2017) · HLA · doi:10.1111/tan.12967 · Cited by 26
Self-citationBrinkman, A. K. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.07.001 · Cited by 28
Metadata
- Authors
- Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., Bonifacio, E., & Eisenbarth, G. S.
- Affiliations
- TUM Klinikum (DE)
- University of Helsinki (FI)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-19
- Volume
- 309
- Issue
- 23
- Pages
- 2473
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4878912
- OpenAlex
- W2095256598
- Semantic Scholar
- 5a7a8cb24a1d4a727e23b19c717a8328b3ce09d6
- Cited by
- 1,312
- References
- 29
- Citations by year
- 2026: 118 · 2025: 133 · 2024: 103 · 2023: 124 · 2022: 107 · 2021: 127 · 2020: 83 · 2019: 92 · 2018: 92 · 2017: 86 · 2016: 89 · 2015: 83 · 2014: 55 · 2013: 18
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Juvenile Diabetes Research Foundation International (4‐1999‐731, 4‐2001‐435)
- Deutsche Forschungsgemeinschaft (/14-2, /14-1)
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Lastentautien Tutkimussäätiö
- National Institutes of Health (DK32493)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK32493, R01DK032493, U01DK063821)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, seroconversion, multiple autoantibodies, progression to diabetes, insulin autoantibodies, GAD65 antibodies, IA-2 autoantibodies, preclinical diabetes, risk prediction, age at seroconversion, islet transplantation
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Diabetes Mellitus, Type 1, Female, Finland, Follow-Up Studies, Genotype, Germany, Glutamate Decarboxylase, Humans, Infant, Insulin, Islets of Langerhans, Male, Prospective Studies, Risk, Disease Progression, Genetic Predisposition to Disease, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
